Literature DB >> 23860709

Better risk assessment with glycated hemoglobin instead of cholesterol in CVD risk prediction charts.

David Faeh1, Sabine Rohrmann, Julia Braun.   

Abstract

Traditional risk charts for the prediction of cardiovascular disease (CVD) include cholesterol parameters. We evaluated how models predict fatal CVD when cholesterol is replaced by glucose parameters. We used data from NHANES III, a US survey conducted 1988-1994 (follow-up until 2006); 15,454 participants (1,716 CVD deaths) were included. Based on the ESC SCORE method, we used age, sex, blood pressure, smoking and either of the following: (1) total cholesterol, (2) total-to-HDL-cholesterol, (3) glucose, (4) glycated hemoglobin (A1C). Scaled Brier score (BS), Nagelkerke's R(2) (NR) and integrated discrimination improvement (IDI) were used for model comparison. The ranking (best to worst) was: A1C (BS = 11.62 %; NR = 0.0865; IDI = 0.0091), glucose (11.16 %; 0.0734; 0.0067), total-to-HDL-cholesterol (9.97 %; 0.0547; 0.0010), cholesterol (9.75 %; 0.0484; 0, reference). Differences between models with cholesterol and glucose or A1C were statistically significant. This study suggests the use of A1C instead of cholesterol parameters in charts to assess CVD risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860709     DOI: 10.1007/s10654-013-9827-6

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  10 in total

1.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

Authors:  R B D'Agostino; S Grundy; L M Sullivan; P Wilson
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

Review 2.  Does lowering of blood glucose improve cardiovascular morbidity and mortality?

Authors:  Nayyar Iqbal; Arthur H Rubenstein
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

3.  Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study.

Authors:  Gerd Assmann; Paul Cullen; Helmut Schulte
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

4.  Body mass index vs cholesterol in cardiovascular disease risk prediction models.

Authors:  David Faeh; Julia Braun; Matthias Bopp
Journal:  Arch Intern Med       Date:  2012-12-10

5.  The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Authors:  Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

6.  Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures.

Authors: 
Journal:  Vital Health Stat 1       Date:  1994-07

7.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Authors:  Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

8.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

10.  Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial.

Authors:  Rimei Nishimura; Tomoko Nakagami; Hirohito Sone; Yasuo Ohashi; Naoko Tajima
Journal:  Cardiovasc Diabetol       Date:  2011-06-30       Impact factor: 9.951

  10 in total
  5 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  The Generation R Study: Biobank update 2015.

Authors:  Claudia J Kruithof; Marjolein N Kooijman; Cornelia M van Duijn; Oscar H Franco; Johan C de Jongste; Caroline C W Klaver; Johan P Mackenbach; Henriëtte A Moll; Hein Raat; Edmond H H M Rings; Fernando Rivadeneira; Eric A P Steegers; Henning Tiemeier; Andre G Uitterlinden; Frank C Verhulst; Eppo B Wolvius; Albert Hofman; Vincent W V Jaddoe
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

Review 3.  Early origins of chronic obstructive lung diseases across the life course.

Authors:  Liesbeth Duijts; Irwin K Reiss; Guy Brusselle; Johan C de Jongste
Journal:  Eur J Epidemiol       Date:  2014-12-24       Impact factor: 8.082

4.  Coronary Heart Disease and Dietary Carbohydrate, Glycemic Index, and Glycemic Load: Dose-Response Meta-analyses of Prospective Cohort Studies.

Authors:  Geoffrey Livesey; Helen Livesey
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-02-26

5.  Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models.

Authors:  Gaurav Gulati; Jenica Upshaw; Benjamin S Wessler; Riley J Brazil; Jason Nelson; David van Klaveren; Christine M Lundquist; Jinny G Park; Hannah McGinnes; Ewout W Steyerberg; Ben Van Calster; David M Kent
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.